Delcath Systems, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, has entered into a debt facility with Avenue Venture Opportunities Fund, providing up to $20 million with an initial $15 million funded at close. Read more.
Delcath Systems Secures $20M Debt Facility with Avenue Venture Opportunities Fund
